Advent-IRBM’s accelerated testing will start on 550 healthy volunteers. If phase 1 trial will successfully pass, the vaccine could be available already in September
Strictest deadlines for drug and vaccines testing have been wavering in the last two months, proof is that the Italian Advent-IRBM located in Pomezia (Rome), in partnership with the Jenner Institute of Oxford University, announced that accelerated clinical trials of its vaccine will start by the end of April.
“Given the results of the past weeks, the first batch of the vaccine will be transferred from Pomezia to England, where accelerated clinical trials will start on 550 healthy volunteers – Pietro Di Lorenzo, CEO of Advent and CNCCS Consortium, President and CEO of IRBM SpA points out -. […] Non-toxicity and efficacy have been tested enough, with particularly positive lab results”.
If phase 1 trial will successfully pass, “we expect to utilize the vaccine already in September to vaccinate medical staff and law enforcement in compassionate use”.
Article by Francesca Cerati published on Il Sole 24 Ore – 13/04/2020
Read the original article on Il Sole 24 Ore